USFDA7 Mar 2026, 06:04 pm
Lupin Ltd Receives Form-483 with Two Observations from U.S. FDA at Ankleshwar Facility
AI Summary
Lupin Ltd, a prominent pharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has concluded an inspection at its manufacturing facility in Ankleshwar, India. The inspection, which took place from March 02, 2026 to March 07, 2026, resulted in the issuance of a Form-483 with two observations. The company has committed to addressing these observations and responding to the U.S. FDA within the specified timeframe. Lupin is dedicated to maintaining compliance with Current Good Manufacturing Practice (CGMP) standards across all its facilities.
Key Highlights
- U.S. FDA inspection conducted at Lupin's Ankleshwar facility from March 02, 2026 to March 07, 2026
- Form-483 with two observations issued by U.S. FDA
- Lupin committed to addressing observations and responding to U.S. FDA within stipulated timeframe
- Company dedicated to maintaining CGMP standards across all facilities